Institute of Molecular and Cell Biology and Experimental Therapeutics Centre will work on compounds.

S*BIO signed a two-year master research collaboration agreement with Singapore’s agency for Science, Technology and Research’s (A*STAR) Institute of Molecular and Cell Biology (IMCB) for the discovery and development of multiple compounds for the treatment of cancer.

Promising compounds may be further developed by A*STAR’s newly formed Experimental Therapeutics Centre (ETC) as well as S*BIO.

Previous articleSciele to Work on Fenofibrate and Pravastatin Combination
Next articleApplied Bio Licenses GE Healthcare Biomagnetic Isolation Patents